5-Amino-1MQ is a small molecule sold across the peptide and longevity market as a fat-loss aid, usually alongside MOTS-c and other “metabolic” injectables. It blocks an enzyme called nicotinamide N-methyltransferase, and in obese mice it does what the sellers claim: less body fat, no drop in food intake. The problem is where the evidence stops. Every data point behind 5-Amino-1MQ comes from a mouse cage, and there is no human trial of it anywhere: no dosing study, no safety study, no test of whether the mouse effect survives contact with a person.
Technically, it is not even a peptide. It is a synthetic small molecule, a methylquinolinium compound, grouped into the “peptide” marketing category because that is where it sells. That labeling looseness is worth flagging on its own, because it tells you something about how thin the regulatory and editorial scrutiny is around this entire product category.
Bottom line: the mechanism is real and the mouse data hold up. The leap from “worked in mice” to “safe and effective for you” has never been tested, by anyone, at all.
What the human and animal evidence shows
There is no peer-reviewed human clinical trial of 5-Amino-1MQ. No case series has been published, no dose-finding study exists, and no one has even run an uncontrolled open-label pilot. Everything published on this compound sits in the mouse literature.
That mouse literature is narrower than the marketing copy suggests. The foundational study, senior-authored by Watowich, tested a series of methylquinolinium NNMT inhibitors, including the compound that came to be known commercially as 5-Amino-1MQ, in diet-induced obese mice.[1] The findings:
Body weight and fat mass dropped. Systemic treatment significantly reduced body weight and white adipose mass and shrank individual adipocytes, compared with untreated controls.[1]
Food intake did not change. The mice ate the same amount and lost weight anyway, which is the detail vendors lean on hardest, and the one part of the story that is well supported.[1]
Cholesterol fell too. Plasma total cholesterol dropped alongside the weight loss, in the same experiment.[1]
What is missing is just as telling. The same search that turned up the weight and food-intake findings found nothing on energy expenditure or adipose tissue inflammation specifically attributable to 5-Amino-1MQ. Sellers routinely claim both. The published record does not support either claim as stated, so this article does not repeat them.
Mechanism: NNMT inhibition, confirmed and hypothesized
5-Amino-1MQ belongs to a class of selective, membrane-permeable NNMT inhibitors, developed and validated for target selectivity in cultured adipocytes and in the liver and adipose tissue of obese mice.[1] The enzyme itself has a well-characterized job.
What NNMT does: it methylates nicotinamide, a precursor of NAD+, using S-adenosylmethionine (SAM) as the methyl donor. That reaction competes with polyamine biosynthesis and histone methylation for the same limited SAM pool inside the cell.[2] Inhibit NNMT, and more nicotinamide stays available for NAD+ synthesis, and more SAM stays available for the pathways it would otherwise have consumed.
The rationale for going after NNMT with a drug did not start with a drug. It started with genetics. Knocking down NNMT in the white adipose tissue and liver of mice protected them from diet-induced obesity, by increasing cellular energy expenditure.[2] That knockdown result is what justified building a small molecule to do the same job pharmacologically. It is a familiar drug-development sequence, the same one that took statins from a genetic observation about LDL receptors to an approved pill, except in this case the sequence has only reached the mouse stage.
That distinction matters more than it sounds. A gene knockdown tells you a target is worth hitting. It tells you nothing about whether a specific drug hits that target cleanly, at a tolerable dose, without off-target effects elsewhere in the body. Blocking a metabolic switch that also touches polyamine synthesis and histone methylation is not automatically safe just because the switch, in one tissue, in one strain of mouse, moved the number you wanted.[2]
Dosing nobody can responsibly give you
This is the section every 5-Amino-1MQ vendor skips, and for good reason. The published record does not establish an administration route, dose, or duration specific to this compound. There is no absorption profile, no half-life, and no human-equivalent dose calculation on record for 5-Amino-1MQ.
That gap is not a paperwork oversight. It is the direct consequence of skipping straight from “worked in mice” to “sold online” without the pharmacokinetic work that normally sits in between. Anyone quoting you a milligram dose for 5-Amino-1MQ is quoting you a number that does not exist in the published literature.
Converting a mouse dose to a human one is not a matter of scaling by body weight. Absorption, metabolism, and clearance rates differ between species in ways that do not follow a simple ratio, which is exactly why drug development runs a full pharmacokinetic program in animals and then a separate one in humans before anyone settles on a dose. For 5-Amino-1MQ, the human half of that program has not started. A number pulled from a mouse protocol and divided down for a person is a guess wearing the clothes of a calculation.
Side effects and safety unknowns
What we don’t know: long-term safety data for 5-Amino-1MQ in humans do not exist, because no human trial has been conducted. Every safety claim you will see about this compound is an extrapolation from a mouse cage rather than a finding about people.
What the animal data do show: NNMT inhibitor treatment in diet-induced obese mice reduced body weight without reducing total food intake, and produced no observable adverse effects over the course of the study, despite the significant drop in body weight and adipose mass.[1] That is a genuinely reassuring finding, as far as it goes. It goes exactly as far as a mouse study goes.
Two things about the mechanism deserve more caution than the marketing gives them:
One-carbon metabolism. NNMT inhibition intersects with a pathway also responsible for DNA methylation. Nobody has studied what chronically redirecting that flux does over months or years, in mice or in people.
No adverse-event registry. Because there is no human trial, there is no structured adverse-event reporting at all. Anecdotal forum reports are not a substitute for one, and this article will not treat them as evidence.
What is established versus what is marketed
Claim | Status in mice | Status in humans |
|---|---|---|
Reduces body weight and fat mass | Established, PMID 29155147 | Not tested |
Reduces food intake | No, unchanged, PMID 29155147 | Not tested |
Improves muscle regeneration after injury | Established in aged mice, PMID 30753815 | Not tested |
Increases energy expenditure | Not established for this compound | Not tested |
Reduces adipose inflammation | Not established for this compound | Not tested |
Safe dosing regimen | Not published | Not established |
Every row draws only on the two mouse studies with verified findings.
Where 5-Amino-1MQ fits against better-studied alternatives
Compare this to the other end of the metabolic-drug spectrum. GLP-1 receptor agonists such as semaglutide have been through multiple large randomized controlled trials in humans, while 5-Amino-1MQ has been through none at all. That is not a difference in degree, it is a difference in kind: one class of compound has passed through the regulatory and clinical gauntlet that turns a mechanism into a medicine, and the other has not left the animal facility.
None of this means the NNMT mechanism is weak. The knockdown data, the small-molecule selectivity work, and the muscle-regeneration findings below are all real, published, peer-reviewed results. What is weak is the inferential leap the marketing makes on top of them, from “this pathway matters in mice” to “this specific product is the answer for you.” Those are different claims, resting on different amounts of evidence, and the industry selling 5-Amino-1MQ has strong financial reasons to blur the line between them.
5-Amino-1MQ is usually sold next to MOTS-c, and the comparison is not flattering to either. The published human research on MOTS-c consists of studies correlating its naturally circulating levels with exercise and metabolic disease, not completed trials of MOTS-c given as a treatment.[3] Two compounds, marketed as a stack, and neither has a human efficacy trial behind it. If you want a fuller picture of which injectable peptides do and do not clear that bar, that comparison is worth reading on its own.
Every finding on this compound stops at the cage door.
What to watch for next
The NNMT-inhibitor research program is not standing still, it is just not moving toward 5-Amino-1MQ specifically. The most interesting recent extension is outside metabolism entirely: in 24-month-old mice, NNMT inhibitor treatment after a muscle injury increased muscle stem cell activity and raised peak contractile torque by about 70 percent compared with controls.[4]
70% increase in peak muscle torque after injury in NNMT inhibitor-treated aged mice, versus controls PMID 30753815
That is a genuinely different application, sarcopenia and injury recovery in old age rather than obesity, and it comes from the same research group and the same drug class. It is also, again, mice. No registered human clinical trial of 5-Amino-1MQ currently appears in public trial registries, for obesity, for muscle recovery, or for anything else.
If a human trial does eventually run, the muscle application is arguably the more interesting one to watch. Obesity drugs compete with GLP-1 agonists that already have a decade of human data behind them. A therapy that could rescue aged, injured muscle would be entering a market with far less competition and a much clearer unmet need. That is speculation about where the incentives point, not a claim about what the compound will do in a person. Nobody knows that yet, including the people selling it to you.
Until one does, the honest description of 5-Amino-1MQ is a validated mouse finding with a marketable name. The mechanism has real biochemistry behind it. The compound has real effects in obese mice. What it does not have, at any dose, in any human being, is a single published data point. Anyone selling you certainty about that gap is selling you something the literature does not contain.
This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.
References
Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice.. Biochemical pharmacology, 2018.
Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity.. Nature, 2014.
The correlation between mitochondrial derived peptide (MDP) and metabolic states: a systematic review and meta-analysis.. Diabetology & metabolic syndrome, 2024.
Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle.. Biochemical pharmacology, 2019.
